Aim: This study was conducted to propose the optimal duration of adjuvant chemotherapy in stage II or III gastric cancer regardless of treatment regimens, which had been introduced from the oral fluoropyrimidine derivatives to the intravenous fluoropyrimidine combined with platinums. We concluded that a prospective cohort study should be performed to figure out the longer period of adjuvant chemotherapy in gastric cancers could obtain much higher OS and RFS. Disclosure: All authors have declared no conflicts of interest.

